457 related articles for article (PubMed ID: 12209029)
1. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.
Abramson SB; Amin A
Rheumatology (Oxford); 2002 Sep; 41(9):972-80. PubMed ID: 12209029
[TBL] [Abstract][Full Text] [Related]
2. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
3. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice.
Inoue K; Masuko-Hongo K; Okamoto M; Nishioka K
Clin Exp Rheumatol; 2003; 21(1):33-9. PubMed ID: 12673887
[TBL] [Abstract][Full Text] [Related]
5. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
Strand V; Kavanaugh AF
Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
[TBL] [Abstract][Full Text] [Related]
6. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
Joosten LA; Helsen MM; Saxne T; van De Loo FA; Heinegard D; van Den Berg WB
J Immunol; 1999 Nov; 163(9):5049-55. PubMed ID: 10528210
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
8. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
9. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
10. IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis.
Gabay C
Expert Opin Investig Drugs; 2000 Jan; 9(1):113-27. PubMed ID: 11060665
[TBL] [Abstract][Full Text] [Related]
11. [Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts].
Seemayer CA; Distler O; Kuchen S; Müller-Ladner U; Michel BA; Neidhart M; Gay RE; Gay S
Z Rheumatol; 2001 Oct; 60(5):309-18. PubMed ID: 11759230
[TBL] [Abstract][Full Text] [Related]
12. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis.
Li X; Yuan FL; Lu WG; Zhao YQ; Li CW; Li JP; Xu RS
Biochem Biophys Res Commun; 2010 Jun; 397(2):131-5. PubMed ID: 20513356
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts.
Neidhart M; Gay RE; Gay S
Arthritis Rheum; 2000 Aug; 43(8):1719-28. PubMed ID: 10943861
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
[TBL] [Abstract][Full Text] [Related]
15. Anticytokine therapy for osteoarthritis: evidence to date.
Malemud CJ
Drugs Aging; 2010 Feb; 27(2):95-115. PubMed ID: 20104937
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction.
Lubberts E; Joosten LA; van Den Bersselaar L; Helsen MM; Bakker AC; van Meurs JB; Graham FL; Richards CD; van Den Berg WB
J Immunol; 1999 Oct; 163(8):4546-56. PubMed ID: 10510398
[TBL] [Abstract][Full Text] [Related]
17. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
[TBL] [Abstract][Full Text] [Related]
18. Anakinra: a review of its use in the management of rheumatoid arthritis.
Waugh J; Perry CM
BioDrugs; 2005; 19(3):189-202. PubMed ID: 15984903
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis with IL-1 inhibitors.
Gabay C; Arend WP
Springer Semin Immunopathol; 1998; 20(1-2):229-46. PubMed ID: 9836379
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
